Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

AMLX | NASDAQ
Chart Builder DCF Calculator
$27.80
-$2.49 (-8.22%)
At close: Nov 16, 2026, 4:00 PM ET
$27.67
-$0.13 (-0.47%)
After-hours: Nov 16, 2026, 7:30 PM ET
-8.22%

Rating

Updated: Nov 16, 2026
31.5
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #755/1021 (Top 74%)

Key Statistics

Market Data

Market Cap $3.57B
1D Range
27.55 31.35
52W Range
11.38 39.66

Valuation (TTM)

PE -19.58
PB 4.74
EV/EBITDA -17.46

Valuation (NTM)

Forward PE N/A
Forward PEG 9.05
Price Target $52.00
Loading financial charts...

Profile

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative co...

Sector Healthcare
Industry Biotechnology
Employees 136
IPO Date Jan 7, 2022
Website amylyx.com
Fiscal Year January - December

Latest News

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript

1 day ago · seekingalpha.com

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

2 days ago · businesswire.com

Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript

11 days ago · seekingalpha.com

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript
Amylyx Pharmaceuticals Q3 Earnings Call Highlights

12 days ago · marketbeat.com

Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences

14 days ago · businesswire.com

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

15 days ago · businesswire.com

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
11 Stocks Most Likely to See a Short Squeeze Rally

1 month ago · schaeffersresearch.com

11 Stocks Most Likely to See a Short Squeeze Rally
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

1 month ago · businesswire.com

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
10 Stocks With Massive Short Squeeze Potential

2 months ago · schaeffersresearch.com

10 Stocks With Massive Short Squeeze Potential
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Earnings

Next Earnings
Mar 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$52.00
Upside
+87.05%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.